Suda Pharmaceuticals Ltd SMA 50
¿Qué es el SMA 50 de Suda Pharmaceuticals Ltd?
El SMA 50 de Suda Pharmaceuticals Ltd es AUD$0 +16.67%
¿Cuál es la definición de SMA 50?
SMA 50 es un precio promedio de las acciones de los últimos 50 días calculado como una media no ponderada de los previos 50 precios de cierre de acciones.
Simple moving average of 50 days for a stock is an unweighted moving average over the past 50 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.
Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.
SMA 50 de compañías en Sector Health Care en ASX en comparadas con Suda Pharmaceuticals Ltd
¿Qué hace Suda Pharmaceuticals Ltd?
Suda Pharmaceuticals Ltd engages in the development of drug delivery technology in Australia, India, Europe and Korea. It offers ZolpiMist, an oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia. The company's product pipeline includes Sumatriptan, an oral spray formulation for the treatment of acute migraine; and anagrelide, a platelet lowering agent for use in thrombosis, which is used for the treatment of cancer. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH and Mitsubishi Tanabe Pharma Singapore for ZolpiMist oral spray; product development, licence, and supply agreement with Cann Pharmaceutical Australia Ltd for the development of novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma, and motion sickness; and feasibility and option agreement with Zelira Therapeutics for the use of cannabinoids for a range of uses, including insomnia, autism, opioid reduction, anxiety, pain, and cancer. The company also has a feasibility study and option agreement with Laboratorios Ordesa, S.L. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.
Empresas con sma 50 similar a Suda Pharmaceuticals Ltd
- Tintina Mines tiene SMA 50 de CAD$0 +67.00%
- Bold Ventures tiene SMA 50 de CAD$0 -32.22%
- Blockmint Technologies tiene SMA 50 de CAD$0 +0.78%
- Olivut Resources tiene SMA 50 de $0 -32.32%
- Freeport Resources tiene SMA 50 de $0 -20.66%
- WMCH Global Investment tiene SMA 50 de HKD$0 -32.35%
- Suda Pharmaceuticals Ltd tiene SMA 50 de AUD$0 +16.67%
- Eurosport Active World tiene SMA 50 de $0 -130.25%
- WWPKG tiene SMA 50 de HKD$0 -15.13%
- Wai Hung tiene SMA 50 de HKD$0 -75.27%
- Gibb River Diamonds tiene SMA 50 de AUD$0 -11.98%
- Sassy Resources tiene SMA 50 de $0 +64.92%
- Orefinders Resources tiene SMA 50 de $0 -8.82%